LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Kodu・Aktsiate loetelu・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Suletud

13.94 8.48

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

12.79

Max

13.94

Põhinäitajad
By Trading Economics
Sissetulek	-6.4M -20M
Müük	-807K 71M
Aktsiakasum	-0.13
Kasumimarginaal	-28.24
Töötajad	624
EBITDA	-7.9M -14M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+55.63% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-282M 2B
Eelmine avamishind	5.46
Eelmine sulgemishind	13.94

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

8.81 / 10.18 Toetus ja vastupanu

Adaptive Biotechnologies Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. mai 2026, 23:31 UTC

Kuumad aktsiad

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20. mai 2026, 22:52 UTC

Suurimad hinnamuutused turgudel

Osisko Shares Fall on Planned Convertible Notes Offering

20. mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20. mai 2026, 23:44 UTC

Tulu

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20. mai 2026, 23:35 UTC

Market Talk

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20. mai 2026, 23:30 UTC

Market Talk

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20. mai 2026, 23:17 UTC

Market Talk

Global Equities Roundup: Market Talk

20. mai 2026, 23:17 UTC

Market Talk

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20. mai 2026, 23:15 UTC

Market Talk

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20. mai 2026, 23:14 UTC

Tulu

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20. mai 2026, 23:02 UTC

Market Talk

KMD Brands Faces Two Testing Hurdles -- Market Talk

20. mai 2026, 22:57 UTC

Market Talk

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20. mai 2026, 22:57 UTC

Market Talk

Global Energy Roundup: Market Talk

20. mai 2026, 22:57 UTC

Market Talk

Global Equities Roundup: Market Talk

20. mai 2026, 22:51 UTC

Market Talk

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20. mai 2026, 22:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. mai 2026, 22:27 UTC

Market Talk

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20. mai 2026, 22:14 UTC

Market Talk

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20. mai 2026, 22:10 UTC

Tulu

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20. mai 2026, 22:00 UTC

Tulu

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20. mai 2026, 21:38 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20. mai 2026, 21:27 UTC

Tulu

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20. mai 2026, 21:20 UTC

Tulu

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20. mai 2026, 21:19 UTC

Tulu

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20. mai 2026, 21:18 UTC

Tulu

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20. mai 2026, 21:17 UTC

Tulu

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20. mai 2026, 21:17 UTC

Tulu

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20. mai 2026, 21:17 UTC

Tulu

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20. mai 2026, 21:16 UTC

Tulu

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Adaptive Biotechnologies Corp Prognoos

Hinnasiht

By TipRanks

55.63% tõus

12 kuu keskmine prognoos

Keskmine 20.17 USD 55.63%

Kõrge 22 USD

Madal 18 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Adaptive Biotechnologies Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Adaptive Biotechnologies Corp aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

8.81 / 10.18Toetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.